Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AMG 199 |
Synonyms | |
Therapy Description |
AMG 199 is a bi-specific T-cell engager (BiTE) antibody that binds to MUC17 and CD3, thereby crosslinking MUC17-expressing tumor cells and T-lymphocytes, potentially resulting in enhanced T-cell response against tumor cells expressing MUC17 (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AMG 199 | AMG199|AMG-199 | CD3 Antibody 99 | AMG 199 is a bi-specific T-cell engager (BiTE) antibody that binds to MUC17 and CD3, thereby crosslinking MUC17-expressing tumor cells and T-lymphocytes, potentially resulting in enhanced T-cell response against tumor cells expressing MUC17 (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04117958 | Phase I | AMG 199 | Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers | Terminated | USA | NLD | FRA | ESP | DEU | AUT | 3 |